These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 39092569)
21. The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway. Wang J; Jiang C; Li N; Wang F; Xu Y; Shen Z; Yang L; Li Z; He C Cell Death Dis; 2020 Aug; 11(8):682. PubMed ID: 32826876 [TBL] [Abstract][Full Text] [Related]
22. TBC1D10B promotes tumor progression in colon cancer via PAK4‑mediated promotion of the PI3K/AKT/mTOR pathway. Chi XJ; Song YB; Zhang H; Wei LQ; Gao Y; Miao XJ; Yang ST; Lin CY; Lan D; Zhang X Apoptosis; 2024 Aug; 29(7-8):1185-1197. PubMed ID: 38824479 [TBL] [Abstract][Full Text] [Related]
23. TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling. Zheng D; Ning J; Deng H; Ruan Y; Cheng F J Transl Med; 2024 May; 22(1):481. PubMed ID: 38773612 [TBL] [Abstract][Full Text] [Related]
24. Galectin-1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and Survival. Su YL; Luo HL; Huang CC; Liu TT; Huang EY; Sung MT; Lin JJ; Chiang PH; Chen YT; Kang CH; Cheng YT Cells; 2020 Mar; 9(4):. PubMed ID: 32225123 [TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway. Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321 [TBL] [Abstract][Full Text] [Related]
26. Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21. Zhu G; Liu X; Li H; Yan Y; Hong X; Lin Z Int J Immunopathol Pharmacol; 2018; 32():2058738418814341. PubMed ID: 30477356 [TBL] [Abstract][Full Text] [Related]
27. NLRP3 in human glioma is correlated with increased WHO grade, and regulates cellular proliferation, apoptosis and metastasis via epithelial-mesenchymal transition and the PTEN/AKT signaling pathway. Yin XF; Zhang Q; Chen ZY; Wang HF; Li X; Wang HX; Li HX; Kang CM; Chu S; Li KF; Li Y; Qiu YR Int J Oncol; 2018 Sep; 53(3):973-986. PubMed ID: 30015880 [TBL] [Abstract][Full Text] [Related]
28. P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway. Wu YL; Liu W; Zhao T; Jin J Med Oncol; 2024 May; 41(6):163. PubMed ID: 38777998 [TBL] [Abstract][Full Text] [Related]
29. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway. Fu Y; Yao N; Ding D; Zhang X; Liu H; Ma L; Shi W; Zhu C; Tang L J Cell Physiol; 2020 Mar; 235(3):2761-2775. PubMed ID: 31531884 [TBL] [Abstract][Full Text] [Related]
30. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Lu C; Shan Z; Hong J; Yang L Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966 [TBL] [Abstract][Full Text] [Related]
31. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis. Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829 [TBL] [Abstract][Full Text] [Related]
32. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway. Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952 [TBL] [Abstract][Full Text] [Related]
33. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway. Li YJ; Wang Y; Wang YY J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801 [TBL] [Abstract][Full Text] [Related]
34. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858 [TBL] [Abstract][Full Text] [Related]
35. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways. Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405 [TBL] [Abstract][Full Text] [Related]
36. Topoisomerase II alpha promotes gallbladder cancer proliferation and metastasis through activating phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway. Lyu WJ; Shu YJ; Liu YB; Dong P Chin Med J (Engl); 2020 Oct; 133(19):2321-2329. PubMed ID: 32925281 [TBL] [Abstract][Full Text] [Related]
37. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway]. Shang L; Jiang W; Zhang J; Wu W Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909 [TBL] [Abstract][Full Text] [Related]
38. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN. Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796 [TBL] [Abstract][Full Text] [Related]
39. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT Cells; 2020 Mar; 9(3):. PubMed ID: 32197467 [TBL] [Abstract][Full Text] [Related]
40. Circular RNA hsa_circ_0010882 promotes the progression of gastric cancer via regulation of the PI3K/Akt/mTOR signaling pathway. Peng YK; Pu K; Su HX; Zhang J; Zheng Y; Ji R; Guo QH; Wang YP; Guan QL; Zhou YN Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1142-1151. PubMed ID: 32096170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]